Similar Posts
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment….
At-home health test maker Thorne explores sale | Reuters News Agency
Business & FinanceDealsHealth 21 July 2023, 6:41 pm 1 minute Reuters exclusively reported that Thorne HealthTech Inc (THRN.O), a provider of at-home health tests and nutritional supplements, is exploring a sale. Market Impact Thorne’s shares ended trading on Friday up 12.9% at $5.95 on the news, giving the company a market value of $320 million….
Celine Dion’s Sister Gives Heart-Wrenching Update On Singer’s Health Battle
At HuffPost, we believe that everyone needs high-quality journalism, but we understand that not everyone can afford to pay for expensive news subscriptions. That is why we are committed to providing deeply reported, carefully fact-checked news that is freely accessible to everyone. Our News, Politics and Culture teams invest time and care working on hard-hitting…
All eyes are on glaucoma, the ‘silent thief of sight’ — and the truth behind 7 myths
To kick off Glaucoma Awareness Month in January, experts are setting the record straight on some common myths about what the American Academy of Ophthalmology (AAO) calls the “silent thief of sight.” Approximately three million Americans have glaucoma. Yet only half of them are aware they have the potentially blinding disease, according to the Centers…
Arkansas man receives world’s first eye transplant
Aaron James lost his nose, mouth and left eye in a work-related accident. Surgeons in New York successfully performed the reconstruction that included a whole-eye implant. His vision was not restored, but the first-of-its-kind procedure may help advance transplant medicine. “If some form of vision restoration occurred, it would be wonderful, but… the goal was…
Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled…
